Skip to main content Back to Top


Liotrix (Levothyroxine/Liothyronine T4/T3)

Products Affected - Description

    • Thyrolar oral tablet, Actavis, 12.5 mcg/3.1 mcg 100 count, NDC 00456-0040-01
    • Thyrolar oral tablet, Actavis, 25 mcg/6.25 mcg 100 count, NDC 00456-0045-01
    • Thyrolar oral tablet, Actavis, 150 mcg/37.5 mcg 100 count, NDC 00456-0060-01
    • Thyrolar oral tablet, Actavis, 100 mcg/25 mcg 100 count, NDC 00456-0055-01
    • Thyrolar oral tablet, Actavis, 50 mcg/12.5 mcg 100 count, NDC 00456-0050-01

Reason for the Shortage

    • Thyrolar tablets from Actavis (formerly Forest) were on shortage due to manufacturing changes.

Available Products

    • No presentations are available.

Estimated Resupply Dates

    • Actavis (formerly Forest) discontinued all Thyrolar presentations in September 2018.


Updated February 11, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 28, 2005 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins